14 Tests in a Comprehensive Metabolic Panel?

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Quick answer:

A comprehensive metabolic panel measures 14 biomarkers across four categories: glucose, electrolytes (sodium, potassium, chloride, CO2), kidney markers (BUN, creatinine), and liver markers (ALT, AST, ALP, bilirubin, albumin, total protein, calcium). Fasting for 8–12 hours is required because glucose is among the 14 measured components.

Read more →

Understand what your blood sugar metabolic testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

What the 14 tests in a comprehensive metabolic panel actually measure

The comprehensive metabolic panel measures 14 distinct biomarkers that fall into four main categories. Glucose tracks your blood sugar control and diabetes risk. The electrolyte group includes sodium, potassium, chloride, and carbon dioxide (CO2), which maintain fluid balance and cellular function.

Kidney function gets evaluated through blood urea nitrogen (BUN) and creatinine, which may reveal how well your kidneys filter waste. Liver health shows up in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin, which may indicate liver cell damage and bile processing.

Protein status comes from albumin and total protein, reflecting your liver's protein production and overall nutritional state. Finally, calcium measures bone health and cellular signaling function.

Think of these 14 tests as a metabolic dashboard. Each marker tells part of the story, but together they may reveal whether your body's core systems are functioning optimally or showing early signs of dysfunction.

Normal versus optimal levels for CMP tests

Reference ranges for the 14 CMP tests represent the middle 95% of apparently healthy people, but "normal" doesn't always mean optimal for you. Glucose normal range is typically 70-99 mg/dL fasting, but levels consistently above 85 mg/dL may indicate early insulin resistance even within the normal range.

Electrolyte ranges are tightly controlled by your body. Sodium runs 136-145 mEq/L, potassium 3.5-5.1 mEq/L, chloride 98-107 mEq/L, and CO2 22-29 mEq/L. Small deviations may signal significant underlying issues.

Kidney markers show function decline gradually. Creatinine normal range is 0.7-1.3 mg/dL for men and 0.6-1.1 mg/dL for women, but levels in the higher normal range may indicate early kidney function decline, especially with rising trends over time.

Your optimal levels depend on your individual baseline, age, fitness level, and health goals. Tracking your personal trends matters more than single measurements, since metabolic health changes gradually before showing up in symptoms.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

What high CMP levels can mean

Elevated glucose above 100 mg/dL fasting may suggest insulin resistance or diabetes development. High BUN (above 20 mg/dL) combined with high creatinine may indicate kidney function decline, though dehydration can temporarily raise both markers.

Liver enzyme elevations tell different stories. High ALT typically may indicate liver cell damage from medications, alcohol, or fatty liver disease. Elevated AST may reflect liver damage but also muscle breakdown from intense exercise. High alkaline phosphatase may suggest bile duct issues or bone disorders.

Electrolyte imbalances have specific associations. High sodium often is associated with dehydration or kidney issues. Elevated potassium may indicate kidney dysfunction or certain medications. High chloride usually follows sodium, while high CO2 may suggest lung or kidney compensation for acid-base imbalances.

High total protein or albumin may indicate dehydration, while high calcium may reflect hyperparathyroidism, certain cancers, or excessive vitamin D supplementation. Context from other markers and symptoms helps determine the underlying cause.

What low CMP levels can mean

Low glucose below 70 mg/dL may indicate hypoglycemia, which can result from diabetes medications, excessive alcohol, or rare insulin-producing tumors. Low BUN might suggest liver dysfunction, malnutrition, or overhydration.

Decreased liver enzymes are rarely concerning, but very low levels might indicate severe liver dysfunction or nutritional deficiencies. Low bilirubin typically isn't clinically significant.

Electrolyte deficiencies create specific symptoms. Low sodium (hyponatremia) can be associated with confusion and seizures, often from overhydration or certain medications. Low potassium may affect heart rhythm and muscle function. Low chloride usually follows sodium deficiencies.

Low protein levels may indicate liver dysfunction, kidney loss, or malnutrition. Low albumin specifically may suggest chronic disease, liver problems, or protein loss through kidneys or intestines. Low calcium may reflect vitamin D deficiency, parathyroid dysfunction, or magnesium deficiency.

How the 14 CMP tests are performed

The comprehensive metabolic panel requires a single blood draw from a vein in your arm. You'll need to fast for 8-12 hours beforehand since glucose measurement requires fasting for accuracy. Water is allowed and encouraged during the fasting period.

The blood sample gets processed through automated analyzers that measure all 14 components simultaneously. Results are typically available within 24-48 hours, though some labs offer same-day processing.

Most doctors recommend CMP testing annually for healthy adults, more frequently if you have diabetes, kidney disease, or liver conditions. The test timing matters for glucose accuracy, so morning draws after an overnight fast provide the most reliable results.

No special preparation beyond fasting is required. Continue taking prescribed medications unless your doctor specifically instructs otherwise, since stopping medications can affect certain markers more than the medications themselves.

What can change your CMP results

Diet significantly impacts several CMP markers. High-carb meals before testing may elevate glucose, while high-protein diets may increase BUN. Dehydration concentrates most markers, making them appear elevated when they're actually normal.

Exercise affects multiple components. Intense workouts may temporarily raise AST, ALT, and creatinine due to muscle breakdown. Endurance exercise may lower glucose through improved insulin sensitivity over time.

Medications influence various markers. Diuretics may alter electrolyte levels, statins may raise liver enzymes, and ACE inhibitors may increase potassium. Even over-the-counter NSAIDs may affect kidney markers with regular use.

Age naturally changes several values. Kidney function typically declines gradually, reflected in slowly rising creatinine. Muscle mass loss with aging can actually lower creatinine despite declining kidney function, masking the decline.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

The 14 CMP tests work best when interpreted alongside related markers. Hemoglobin A1c provides a 3-month glucose average that complements the single-point glucose measurement, revealing long-term blood sugar control patterns.

Insulin levels help interpret glucose results, since high glucose with high insulin may suggest insulin resistance, while high glucose with low insulin may indicate diabetes progression. Magnesium affects both calcium and potassium balance.

Thyroid markers like TSH influence metabolism and may explain certain CMP patterns. Inflammatory markers such as CRP help distinguish whether elevated liver enzymes reflect inflammation versus direct liver damage.

Lipid panels complement the metabolic picture, since triglycerides often correlate with glucose patterns and insulin resistance. Together, these expanded panels may reveal metabolic syndrome development before individual components reach concerning levels.

Why testing the 14 CMP components is worth it

Research suggests the comprehensive metabolic panel may show markers associated with health changes years before symptoms appear. Early insulin resistance shows up in glucose trends long before diabetes diagnosis. Kidney function decline may become apparent through creatinine rises before you feel any effects.

These 14 tests cost-effectively screen for multiple conditions simultaneously. A single blood draw may help identify markers associated with diabetes risk, kidney disease, liver dysfunction, and electrolyte disorders that would require separate specialist visits if caught later.

Tracking CMP trends over time provides actionable health insights. Rising glucose patterns can motivate dietary changes that may help reduce the risk of diabetes. Improving kidney markers can confirm that blood pressure management is working effectively.

The metabolic panel also establishes your personal baseline for future comparison. Your optimal creatinine, glucose, and electrolyte levels become reference points for detecting meaningful changes as you age or modify your health approach.

Get your complete metabolic picture

Understanding what the 14 tests in a comprehensive metabolic panel measure is just the beginning. These markers work together to may reveal your metabolic health, but they're even more powerful when combined with additional biomarkers that standard panels miss.

Superpower's Metabolic Health Panel includes all 14 CMP tests plus insulin, leptin, adiponectin, and other metabolic hormones that may reveal the complete picture of your metabolic function. You'll understand not just what your numbers are, but why they're changing and how to optimize them.

Order your Metabolic Health Panel to see how your comprehensive metabolic panel fits into your broader metabolic health story.

Frequently Asked Questions

References

  1. Tyagi A, Aeddula NR (2023). *Azotemia (Archived)*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538145/
  2. American Diabetes Association Professional Practice Committee (2024). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. *Diabetes care*, *47*(Suppl 1), S20-S42. https://doi.org/10.2337/dc24-S002
  3. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A, Israeli Diabetes Research Group (2005). Normal fasting plasma glucose levels and type 2 diabetes in young men. *The New England journal of medicine*, *353*(14), 1454-62. https://doi.org/10.1056/NEJMoa050080
  4. Moman RN, Gupta N, Singh C, Varacallo MA (2026). *Physiology, albumin*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459198/
  5. Rout P, Badireddy M (2025). *Hyponatremia*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470386/
  6. Shahbaz H, Rout P, Gupta M (2024). *Creatinine clearance*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK544228/
  7. Lala V, Zubair M, Minter DA (2023). *Liver function tests*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482489/
  8. Goyal A, Anastasopoulou C, Ngu M, Singh S (2023). *Hypocalcemia*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430912/
  9. Weinstein JR, Anderson S (2010). The aging kidney: physiological changes. *Advances in chronic kidney disease*, *17*(4), 302-7. https://doi.org/10.1053/j.ackd.2010.05.002
  10. Moriles KE, Zubair M, Azer SA (2024). *Alanine aminotransferase (ALT) test*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559278/
  11. Banfi G, Colombini A, Lombardi G, Lubkowska A (2012). Metabolic markers in sports medicine. *Advances in clinical chemistry*, *56*, 1-54. https://doi.org/10.1016/b978-0-12-394317-0.00015-7
  12. Lowe D, Sanvictores T, Zubair M, John S (2026). *Serum alkaline phosphatase: Clinical and laboratory perspectives*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459201/
  13. Muhsin SA, Mount DB (2016). Diagnosis and treatment of hypernatremia. *Best practice & research. Clinical endocrinology & metabolism*, *30*(2), 189-203. https://doi.org/10.1016/j.beem.2016.02.014
  14. Simon LV, Rout P (2025). *Hyperkalemia*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470284/
  15. Berend K, van Hulsteijn LH, Gans RO (2012). Chloride: the queen of electrolytes?. *European journal of internal medicine*, *23*(3), 203-11. https://doi.org/10.1016/j.ejim.2011.11.013
  16. Castera MR, Borhade MB (2025). *Fluid management*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532305/
  17. Helbing A, Leslie SW, Levine SN (2026). *Primary hyperparathyroidism*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441895/
  18. Mathew P, Thoppil D (2022). *Hypoglycemia*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534841/
  19. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC (2004). Electrocardiographic manifestations: electrolyte abnormalities. *The Journal of emergency medicine*, *27*(2), 153-60. https://doi.org/10.1016/j.jemermed.2004.04.006
  20. Castro D, Sharma S (2025). *Hypokalemia*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482465/
  21. Schwingshackl L, Hoffmann G (2014). Comparison of high vs. normal/low protein diets on renal function in subjects without chronic kidney disease: a systematic review and meta-analysis. *PloS one*, *9*(5), e97656. https://doi.org/10.1371/journal.pone.0097656
  22. Lippi G, Salvagno GL, Montagnana M, Brocco G, Guidi GC (2005). Influence of short-term venous stasis on clinical chemistry testing. *Clinical chemistry and laboratory medicine*, *43*(8), 869-75. https://doi.org/10.1515/CCLM.2005.146
  23. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF (2016). Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. *Diabetes care*, *39*(11), 2065-2079. https://doi.org/10.2337/dc16-1728
  24. Rosenberg K (2022). Electrolyte Disorders Common in Thiazide Diuretic Users. *The American journal of nursing*, *122*(1), 59. https://doi.org/10.1097/01.NAJ.0000815448.98112.f5
  25. Desai CS, Martin SS, Blumenthal RS (2014). Non-cardiovascular effects associated with statins. *BMJ (Clinical research ed.)*, *349*, g3743. https://doi.org/10.1136/bmj.g3743
  26. Keen MU, Aeddula NR (2023). *Analgesic nephropathy*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK541101/
  27. Aldenbratt A, Lindberg C, Johannesson E, Hammarsten O, Svensson MK (2022). Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine?. *Journal of nephrology*, *35*(2), 493-503. https://doi.org/10.1007/s40620-021-01122-x
  28. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group (2008). Translating the A1C assay into estimated average glucose values. *Diabetes care*, *31*(8), 1473-8. https://doi.org/10.2337/dc08-0545
  29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*, *28*(7), 412-9. https://doi.org/10.1007/BF00280883
  30. Huang CL, Kuo E (2007). Mechanism of hypokalemia in magnesium deficiency. *Journal of the American Society of Nephrology : JASN*, *18*(10), 2649-52. https://doi.org/10.1681/ASN.2007070792
  31. Mullur R, Liu YY, Brent GA (2014). Thyroid hormone regulation of metabolism. *Physiological reviews*, *94*(2), 355-82. https://doi.org/10.1152/physrev.00030.2013
  32. Singh B, Goyal A, Patel BC (2025). *C-reactive protein: Clinical relevance and interpretation*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441843/
  33. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. *Annals of internal medicine*, *139*(10), 802-9. https://doi.org/10.7326/0003-4819-139-10-200311180-00007
  34. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, *120*(16), 1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  35. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB (2021). Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*, *326*(8), 736-743. https://doi.org/10.1001/jama.2021.12531
  36. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *The New England journal of medicine*, *346*(6), 393-403. https://doi.org/10.1056/NEJMoa012512
  37. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group (2003). Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Annals of internal medicine*, *139*(4), 244-52. https://doi.org/10.7326/0003-4819-139-4-200308190-00006

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey